Genocea Biosciences Inc (GNCA) Drops 6.71% on January 29

Equities Staff |

Genocea Biosciences Inc (GNCA) was one of the Russell 2000's biggest losers for Friday January 29 as the stock slid 6.71% to $3.06, a loss of $-0.22 per share. Starting at an opening price of $3.29 a share, the stock traded between $3.03 and $3.37 over the course of the trading day. Volume was 107,461 shares over 606 trades, against an average daily volume of 312,048 shares and a total float of 28.12 million.

The losses send Genocea Biosciences Inc down to a market cap of $86.03 million. In the last year, Genocea Biosciences Inc has traded between $16.18 and $3.10, and its 50-day SMA is currently $5.33 and 200-day SMA is $9.32.

Genocea Biosciences Inc is a clinical stage biopharmaceutical company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today.

Genocea Biosciences Inc is based out of Cambridge, MA and has some 57 employees. Its CEO is William D. Clark.

For a complete fundamental analysis analysis of Genocea Biosciences Inc, check out Equities.com’s Stock Valuation Analysis report for GNCA. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Kiwa Bio-Tech Products Group Corp

Kiwa Bio-Tech Products Group Corp develops, manufactures, distributes and markets, cost-effective and environmentally safe bio-technological products for agriculture in China.

Private Markets

GoCoin

Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…

8tracks

Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.